Resources
What Should My Business Test For? An Employer’s Guide to Drug Testing Panels
· All articles · Industries · FAQ
The real question is usually: how do we choose the right testing program without overcomplicating operations? Lab nicknames like “5-panel” or “10-panel” still vary by vendor—so the signed requisition, not hallway shorthand, is what matters.
Use this guide to match business risk and scheduling reality to the screen you authorize: who works where, what contracts require, what state law allows, and how much MRO follow-up your HR team can absorb. Confirm details with your TPA and counsel whenever programs cross state lines or DOT boundaries.
Quick decision guide
DOT-covered role → use the DOT-required panel for that collection. DOT drug testing follows federal drug panels and accredited labs—you order through your DER or TPA with the correct test reason, not a custom mix.
Basic hiring or random testing on a non-DOT roster → start with a standard 5-panel drug test–style workplace screen your handbook already authorizes. It keeps scheduling, donor communication, and MRO volume predictable while you prove out the program.
Higher-risk site, sharper contract language, or credible diversion concerns → consider an expanded 10-panel drug test–style bundle only when leadership and counsel have already updated policy and employees know what is changing.
Alcohol concern → treat Breath alcohol testing as its own workflow (windows, devices, and who can order). It usually runs beside—not inside—a urine drug panel.
Tampering or substitution worries → ask your TPA about specimen validity testing (SVT) on urine programs, and still use observation when your rules require it—SVT adds lab signals; it does not replace a sound site process.
Read this first
Segregate paths: regulated drivers and other DOT-covered staff stay on DOT drug testing orders; everyone else follows Non-DOT drug testing and your written policy.
If a drug or validity add-on is not spelled out for employees, do not spring it on supervisors at the collection chair—misaligned messaging creates churn, refusals, and rework.
Every extra analyte can add cost and MRO touches. Expand panels when contracts, injury risk, or diversion patterns justify the operational load—not because a lab brochure looked thorough.
Why “panel” labels are slippery
“Five-panel” and “ten-panel” are shorthand, not guarantees. Two labs can ship different drug lists under the same nickname—budget, legal exposure, and donor communication all hinge on the actual line items on the order.
DOT drug testing follows federal specimen rules; non-DOT workplace testing follows policy and state law, then whatever your lab and MRO can support. When someone says “test for everything,” translate it into roles, incidents, legal limits, and how results will be reported before you widen the menu.
Which panel fits which employer?
Start with who is in scope and what incident or contract pressure you are solving—then match the lab package. Three common buckets:
DOT / federally regulated testing
Operations impact: predictable federal drug panels and paperwork for covered safety-sensitive staff—no swapping analytes because a site prefers a different menu.
Panels and labs are defined by DOT rules; your consortium or TPA implements them. Order the right test reason and modality (urine vs oral fluid drug testing where allowed) for the employee’s role.
Standard employer (often five-drug-style) panels
Operations impact: faster donor communication, leaner MRO queues, and easier scheduling for everyday hiring or random cycles when a narrower screen matches the risk.
Many non-DOT programs start with a 5-panel drug test–style core—often discussed as amphetamines, cocaine, THC, opiates, and PCP—but exact bundles and cutoffs differ by lab. Counsel should confirm the list matches your handbook and state THC rules before rollout.
Broader panels for higher-risk environments
Higher-risk workplaces sometimes expand panels when injury risk, customer contracts, or diversion concerns justify extra screening—and the HR workload that comes with it.
“Ten-panel” is slang; count analytes on the order. Adds such as benzodiazepines, barbiturates, expanded opioids, or methadone raise cost and MRO outreach—include only what policy already explains to employees.
Compare common panel approaches (plain English)
Use this table with your TPA as a cross-check. The signed lab order—not this article—defines what you bought.
| Approach | What it usually means | When employers reach for it |
|---|---|---|
| Regulated (DOT) drug test | Federally specified drug panel and procedures for covered testing—not interchangeable with a random non-DOT screen. | CDL and other DOT safety-sensitive roles; order through your DER/TPA with the correct test reason so dispatch matches the regulated package. |
| Five-panel-style workplace bundle | Often centers on a small set of common drugs of abuse; exact drugs and codes vary by lab. | Baseline hiring or random programs when a 5-panel drug test–style screen matches policy, state law, and the risk you are actually managing. |
| Expanded / ten-panel-style (+) bundle | Adds categories such as benzodiazepines (BZO), barbiturates (BAR), methadone (MTD), or other analytes per lab package. | Higher-hazard sites, contract language, or diversion risk where leadership accepts higher cost and more MRO follow-up. |
| Expanded opiate / opioid coverage | May add or emphasize semi-synthetic opioids (for example oxycodone) or fentanyl-class drugs depending on menu—terminology differs by lab. | Opioid risk spikes, certain post-accident programs, or customer QA clauses—always verify analytes by name on the order. |
| Alcohol programs | Workplace alcohol testing is often a separate workflow from a urine drug panel—breath alcohol testing under DOT rules, or policy-driven breath/EtG strategies for non-DOT when approved. | Post-accident windows, reasonable suspicion with behavioral cues, or random alcohol where devices, observers, and policy line up. |
| Add-on: specimen validity testing (SVT) | Laboratory checks that help detect tampering or invalid specimens—scoped by lab and program. | Turnover-heavy sites, substitution rumors, or post-incident glare where you want extra lab integrity signals alongside—not instead of—solid site controls. |
5-panel drug test vs 10-panel drug test is really a business question: which roles, which incidents, which state rules—and which analytes your TPA files on the requisition.
Why employers add more than a “basic” panel
Expansion is almost always driven by contracts, incidents, or believable risk—not curiosity. Each add shifts budget, scheduling, and how often your MRO phones employees about legitimate prescriptions.
Alcohol: Breath alcohol testing usually sits beside urine drug panels with its own clocks—especially after crashes or suspicion events. EtG/EtS urine markers are a different window; use only when policy and review paths fit.
Opioids / fentanyl: add expanded opioid or fentanyl coverage when lab menus and updated handbook language already support it—otherwise you create confusion at the door.
Sedatives (for example BZO, BAR, MTD): expect higher MRO volume; include when diversion or role access truly warrants the HR load.
SVT: specimen validity testing adds lab integrity signals for dilution or adulteration—it complements, not replaces, observation when your program requires it.
Specimen type: oral fluid drug testing, hair, or blood changes detection windows and legal angles—pick matrix, panel, and policy together with your TPA so operations are not caught mid-shift without the right collector supplies.
What is specimen validity testing (SVT)?
SVT is how labs flag suspicious urine chemistry—substitution, dilution, or adulteration—before your MRO ever interprets drug positives. Operationally it reduces “he said / she said” about watered samples when paired with clear supervisor scripts.
Turn it on when turnover, post-accident glare, or past incidents make tampering plausible. Train supervisors not to treat a flag as automatic discipline before review.
Adulterants and chemical masking
Labs scan for oxidizers, odd pH, and other fingerprints of additives. Keep using observed collections when your rules require them—SVT is an extra signal, not a substitute.
Dilution and abnormal fluid balance
Heavy water loading can dilute urine; labs may flag creatinine and specific gravity patterns. Spell in policy how dilute results are handled after review so supervisors are not improvising.
Synthetic urine and substitution patterns
Synthetic products exist; labs combine validity signals with tight site discipline and refusal rules. Pair with observation when the business stakes are high.
The Role of the Medical Review Officer (MRO)
An MRO is the physician gate between raw lab drama and the verified result HR is allowed to act on—critical when prescriptions are common in your workforce.
DOT follows Part 40; non-DOT paths depend on your policy and lab setup. We collect specimens and paperwork; we are not the MRO. Your TPA and counsel define how verified results feed discipline or return-to-duty steps.
Substance and panel glossary (employer cheat sheet)
Marijuana (THC)
THC hits payroll, reasonable suspicion, and public perception harder than almost any other analyte—especially where state cannabis laws conflict with federal customers.
Labs target THC-related metabolites or parent compounds by specimen and method. Align handbook language, counsel guidance, and the lab menu before you promise leadership a specific outcome.
Cocaine (COC)
Still a common stimulant-risk screen on baseline workplace panels when policy covers cocaine exposure.
Reporting is cutoff- and lab-specific—verify how positives read on the order before supervisors interpret slang.
Opiates vs. expanded opioids
Legacy opiate bundles focused on morphine/codeine/heroin-class chemistry; many employers now widen coverage for semi-synthetic opioids (for example oxycodone, hydrocodone) when contracts or incident history demand it.
Invoice nicknames rarely match clinical speech—read the analyte list with your TPA before you publish a “new panel” to employees.
Fentanyl
Add fentanyl-class coverage when opioid risk, post-incident learning, or customer QA language truly warrants another MRO-heavy category.
Labs bundle fentanyl differently—confirm whether it is embedded in an opioid package or a stand-alone add-on before you budget and communicate.
Amphetamines (AMP / MAMP)
Stimulant screens affect a lot of legitimate prescriptions; expect MRO outreach when ADHD medications are common in your workforce.
Depending on lab design, chemistry may overlap with MDMA discussions—define reporting on the order so supervisors are not guessing.
Phencyclidine (PCP)
Often still bundled for legacy parity; prevalence varies. Drop it only when counsel and contracts agree the risk no longer justifies the line item.
MDMA / ecstasy
Shows up on some expanded stimulant packages—translate supervisor “party drug” language into the exact code on the requisition.
Barbiturates (BAR)
Older sedative class; useful when medical diversion is plausible. Usually an expanded-panel add, not a default for every roster.
Benzodiazepines (BZO)
Anti-anxiety medications are common in the general population—adding BZO increases MRO calls and slows hiring if you are not ready.
Include when policy, risk, and employee communications already explain why sedatives matter for safety-sensitive work.
Methadone (MTD)
Distinct from generic opiate bundles when you need clarity on maintenance therapy contexts—only add if HR and MRO workflows are ready.
Methaqualone (MTQ)
Rare on modern menus; include only when policy and medical review expectations justify paying for a legacy code.
Propoxyphene (PPX)
Mostly obsolete—confirm with the lab before you keep paying for PPX on autopilot renewals.
Alcohol: breath vs. EtG / EtS
Breath alcohol testing gives a near-real-time snapshot for DOT or policy-driven programs with clear observation rules.
EtG/EtS urine markers cover different windows than breath; use only when timelines and MRO expectations fit. PEth is blood-based specialty monitoring—not a swap for DOT breath rules.
How to choose the right program
Stack decisions in this order—the first constraint that applies usually wins.
By industry and customer contracts
Start with what you already signed: transportation, energy, manufacturing, and healthcare-adjacent employers often inherit insurer questionnaires or owner-client QA clauses that name minimum testing. Map those obligations to a lab package before you debate internal “nice to haves.”
By job risk
Machinery, heights, lone work, or medication access usually push broader panels and clearer post-accident triggers; desk-heavy populations rarely need the same chemistry unless policy says otherwise.
By DOT vs. non-DOT
By policy goals
Hiring, random deterrence, post-incident documentation, and reasonable suspicion carry different time pressures. Match panel, specimen, and alcohol orders to the scenario (for example drugs plus breath alcohol testing when policy demands both).
By testing reason: pre-employment, random, post-accident
Pre-employment: align with offer letters and state notice rules. Random: publish stable panel definitions so selections feel fair. Post-accident: follow written triggers so supervisors are not inventing scope on the worst day of the quarter.
Before you lock the panel in writing
Ask your TPA for a one-page analyte list (abbreviations, cutoffs, MRO notes) and brief supervisors—rumor is not training.
Revisit panels after THC law shifts, insurance renewals, or serious incidents; stale menus quietly drift from operations reality.
Turn the panel plan into workable collections
Share DOT vs non-DOT paths, roles, and testing reasons—we help align on-site and mobile visits with the orders your TPA and lab already expect, so supervisors are not improvising at the door.